Showing 1731-1740 of 2320 results for "".
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- Derms Give Back: Caring for Veteranshttps://practicaldermatology.com/news/derms-give-back-caring-for-veterans/2460989/Caring for veterans inspires dermatologists like Joshua E. Lane, MD every single day. Dr. Lane practices in Columbus, GA, near Fort Benning, a large military base, and many of his patients are veterans. He was so moved by their service and selflessness that he joined the
- With New Agreement, DermTech Melanoma Test Available Through DermatologistOnCallhttps://practicaldermatology.com/news/with-new-agreement-dermtech-melanoma-test-available-through-dermatologistoncall/2460987/The DermTech Melanoma Test is now available through DermatologistOnCall’s telemedicine platform. The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via t
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- Janssen Launches National Biologic Coordinators Dayhttps://practicaldermatology.com/news/janssen-launches-national-biologic-coordinators-day/2460973/It’s National Biologic Coordinators Day. Janssen Pharmaceuticals has launched the first national awareness day on November 1 to recognize Biologic Coordinators’ daily commitment to patient care. Even as the use of biologic therapies continues to exp
- Potential Melanoma Treatment Breakthrough: Is KDM5B the Key?https://practicaldermatology.com/news/potential-melanoma-treatment-breakthrough-is-kdm5b-the-key/2460964/The enzyme KDM5B may suppress anti-melanoma immunity, and these findings could help lead to the development of a new treatment strategy to benefit patients with melanoma and other cancers, according to a new study out of the Yale Cancer Center in New Haven, Conn. The research
- Study Seeks to Evaluate V. Dox Technology's Ability to Improve Healing Following HS Surgical Procedurehttps://practicaldermatology.com/news/study-seeks-to-evaluate-v-dox-technologys-ability-to-improve-healing-following-hs-surgical-procedure/2460958/The first patient has been enrolled in a new study using Vomaris Innovations, Inc.’s s bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS). When tunnels develop under the skin in HS, a surgical procedure called deroofing i
- Reistone’s Topical JAK Inhibitor Performs Well in Mild to Moderate ADhttps://practicaldermatology.com/news/reistones-topical-jak-inhibitor-performs-well-in-mild-to-moderate-ad/2460951/Reistone Biopharma’s SHR0302 ointment performed well in a Phase 2 study of patients with mild-to-moderate atopic dermatitis (AD), the company reports. SHR0302 ointment, a topical, selective JAK1 inhibitor, met key primary and secondary endpoints, demonstrating significant improvem
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented